Shares of Harrow Inc. (HROW) are up over 20% at $28.42 in premarket trading Tuesday, following encouraging preliminary financial results for the fourth quarter and year ended December 31, 2024, as well as revenue guidance for 2025.
This eye care pharmaceutical company is engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. The company sells prescription medications directly through its pharmacy, outsourcing facility, and third-party logistics (3PL) partner.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com